A new once-daily pill almost doubled the survival time for patients battling an aggressive and advanced form of pancreatic cancer when compared to chemotherapy in a recent trial.
Experts are hailing the drug, daraxonrasib, as "landscape-changing" for those affected by the disease, noting its additional benefit of causing fewer side effects.
